Neboglamine

Another names: CR-2249, XY-2401 and Nebostinel.
Positive allosteric modulator of the glycine site of the NMDA receptor, which is linked to improved cognition and memory.
Also shows potential as an antipsychotic, particularly for schizophrenia and cocaine dependence, by increasing neuronal activity in key brain areas like the prefrontal cortex.
Safe dose range of 10 to 600 mg per day.
Preferred range of 30 to 300 mg per day.
Research suggests it enhances cognition and memory, as demonstrated in animal models, where it shows cognition- and memory-enhancing effects.
Studies showing it increases neuronal activation in areas relevant to schizophrenia, potentially addressing negative and cognitive symptoms.
Binds very weakly to the NMDA receptor recognition site (IC50 0.7 mM) and shows no significant binding affinity to AMPA and kainic receptors, suggesting a selective action at the glycine site (source).
Antipsychotic-like effects are further evidenced by its ability to inhibit phencyclidine (PCP)-induced hyperlocomotion and rearing behavior in rat models, supporting its clinical evaluation for schizophrenia treatment.